Dongwon Industries, the holding firm of Dongwon Group, signed a memorandum of understanding with Boryung Partners recently to acquire a controlling stake in Boryung Biopharma, which is estimated to be worth 500 billion won ($384 million). Once the acquisition deal is finished, Dongwon Group will be able to enter the biopharmaceutical industry for the first time in its 54-year history.